AUSTIN, Texas, Jan. 16, 2013 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced that it expects to report results for the fourth quarter of 2012 on Monday, February 4, 2013. A press release announcing the results is scheduled for release after the close of trading.

(Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)

Management will hold a conference call to discuss the operating highlights and financial results for the fourth quarter and twelve months ended December 31, 2012 on February 4, 2013, at 5:00 p.m. Eastern time.

The conference call will be webcast live and will be accompanied by a slide presentation, both of which may be accessed at Luminex Corporation's website at http://www.luminexcorp.com. Simply log on to the website, go to the About Us section and access the Investor Relations link. Please go to the website at least 15 minutes prior to the call to register, download and install any necessary audio/video software. If you are unable to participate during the live webcast, the call and slides will be archived for six months on the website using the 'replay' link.

The use of pop-up blocking software may impair your ability to view webcasts. If you use this software, press and hold the CTRL key when you click on the Register button. Please contact your IT group if you are unable to override this feature. Unauthorized recording or downloading of this event is not permitted.

About Luminex Corporation

Luminex is committed to applying its passion for innovation toward advancing healthcare and research worldwide. The Company is transforming global healthcare and life-science research through the development, manufacturing and marketing of proprietary instruments and assays utilizing xMAP^® open-architecture, multi-analyte platform and MultiCode^® real-time polymerase chain reaction (PCR) and multiplex PCR-based technologies, that deliver cost-effective and rapid results to clinicians and researchers. Luminex's technology is commercially available worldwide and in use in leading clinical laboratories as well as major pharmaceutical, diagnostic, biotechnology and life-science companies. The Company is meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, bio-defense research and food safety. For further information on Luminex Corporation and the latest advances in multiplexing using award winning technology, please visit http://www.luminexcorp.com.

Statements made in this release that express Luminex Corporation's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements. Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex's products, the Company's dependence on strategic partners for development, commercialization and distribution of products, concentration of the Company's revenue in a limited number of strategic partners, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle and bulk purchases of consumables, Luminex's ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels, potential shortages of components, competition, the timing of regulatory approvals, the implementation, including any modification, of the Company's strategic operating plans, risks and uncertainties associated with implementing our acquisition strategy and the ability to integrate acquired companies or selected assets into our consolidated business operations, as well as the risks discussed under the heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission. The forward-looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Luminex Corporate Contact:
Harriss T. Currie
Chief Financial Officer and Vice President, Finance
512-219-8020
hcurrie@luminexcorp.com

Luminex Investor Relations Contact:
Matthew D. Scalo
Sr. Director of Investor Relations
512-219-8020
mscalo@luminexcorp.com

SOURCE Luminex Corporation